News Center
Details
The Top 100 Pharmaceutical Companies List Has Been Released—Renfu Pharmaceutical Ranks 19th.
Release time:
2025-07-31 13:37
Source:
On July 6, the 42nd National Pharmaceutical Industry Information Annual Conference, hosted by the China Pharmaceutical Industry Information Center and themed “Exploring Life, Co-creating the Future,” was held in Changping District, Beijing. During the conference, the “Top 100 Chinese Pharmaceutical Companies by Main Business Revenue for 2024” were announced, with Renfu Pharmaceutical Group ranking 19th. From 28th place in 2021 to 19th in 2024, the company has steadily improved its ranking for four consecutive years and has been listed on the ranking for 16 consecutive years.
“The Top 100 Chinese Pharmaceutical Industry Enterprises by Main Business Revenue for 2024” (also known as the “Top 100 Pharmaceutical Industry Enterprises”). This list is derived from objective data in the “2024 China Pharmaceutical Industry Statistical Yearbook” and comprises the top 100 enterprises ranked by main business revenue in the comprehensive volume. In 2024, as outstanding representatives of China’s pharmaceutical industry, these Top 100 enterprises demonstrated strong resilience and played a leading, exemplary role, driven by innovation and underpinned by quality, even amid overall industry pressures and a complex and ever-changing market environment.
Data show that among the top 100 enterprises, 42 achieved double-digit growth in both their main business revenue and total profits. Among these, 15 enterprises saw double-digit growth rates in both indicators. On the other hand, 31 enterprises experienced a double-digit decline in both indicators, with 17 of them recording declines exceeding 10%. The number of domestically-funded, foreign-invested, Hong Kong, Macao, and Taiwan-invested, and Sino-foreign joint venture/cooperative enterprises stood at 66, 15, 13, and 6 respectively, accounting for 63.1%, 17.6%, 15.7%, and 3.5% of the total main business revenue, respectively.
Renfu Pharmaceutical adheres to a development strategy of “becoming a leader in niche pharmaceutical markets,” continuously strengthening and enhancing its competitive edge in core business areas, thereby maintaining a steady growth momentum. In 2024, the company achieved operating revenue of 25.435 billion yuan, marking the sixth consecutive year of revenue exceeding 20 billion yuan.
In the future, Renfu Pharmaceutical will join the development wave of China Merchants Group’s “Third Entrepreneurship,” focusing its efforts on “stability, integration, innovation, and expansion.” Guided by the MAGIC business strategy, we will leverage technological innovation to empower industrial development, cultivate new forms of productive forces, and comprehensively build a path toward high-quality enterprise development. We are committed to becoming a world-class life sciences enterprise, contributing even more to the nation’s pharmaceutical sector and to the health and well-being of the people.
Top 100 Pharmaceutical Industry List Released,Renfu Pharmaceutical ranks 19th.
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd